Low-molecular-weight heparin: Prophylaxis and treatment of venous thromboembolism

Annual Review of Medicine

Volumn 48, Issue , 1997, Pages 79-91

  Pineo, Graham F ^a   Hull, Russell D ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Deep vein thrombosis; Heparin; Low molecular weight heparin; Prevention; Treatment

Indexed keywords

DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN; WARFARIN;

HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; VEIN THROMBOSIS;

FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFUSIONS, INTRAVENOUS; THROMBOPHLEBITIS; TREATMENT OUTCOME;

EID: 0031047458     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.48.1.79     Document Type: Review

References (98)

1. Hirsh J, Raschke R, Warkentin TE, et al. 1995. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 108(4):258-75S
2. Lane DA. 1989. Heparin binding and neutralizing protein. In Heparin, Chemical and Biological Properties, Clinical Applications, ed. DA Lane, U Lindahl, 189: 363-91. London: Edward Arnold
3. Lindahl U, Backstrom G, Hook M, et al. 1979. Structure of the antithrombin-binding site of heparin. Proc. Natl. Acad. Sci. USA 76:3198-302
4. Lindahl U, Thunberg L, Backstrom G, et al. 1984. Extension and structural variability of the antithrombin-binding sequence in heparin. J. Biol. Chem. 259:12368-76
5. Rosenberg RD, Lam L. 1979. Correlation between structure and function of heparin. Proc. Natl. Acad. Sci. USA 76:1218-22
6. a) activity containing the minimal antithrombin III-binding sequence. Biochem. J. 197: 599-609
7. Weitz JI, Hudoba M, Massel D, et al. 1990. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. 86:385-91
8. Salzman EW, Rosenberg RD, Smith MH, et al. 1980. Effect of heparin and heparin fractions on platelet aggregation. J. Clin. Invest. 65:64-73
9. Tollefsen DM, Majerus DW, Blank MK. 1982. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J. Biol. Chem. 257(5):2162-69
10. Hoppensteadt D, Walenga JM, Fasanella A, et al. 1995. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfactionated heparin and low molecular weight heparin. Thromb. Res. 77(2):175-85
11. Barzu T, Molho P, Tobelem G, et al. 1984. Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture. Nouv. Rev. Fr. Haematol. 26:243-47
12. Blajchman MA, Young E, Ofosu FA. 1989. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann. NY Acad. Sci. 556:245-54
13. Bara L, Billaud E, Gramond G, et al. 1985. Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutanteous administration. Thromb. Res. 39:631-36
14. Bjornsson T, Wolfram BS, Kitchell BB. 1982. Heparin kinetics determined by three assay methods. Clin. Pharmacol. Ther. 31: 104-13
15. Levine M, Hirsh J, Gent M, et al. 1994. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acture venous thromboembolism requiring large daily doses of heparin. Arch. Intern. Med. 154:49-56
16. Theroux P, Waters D, Latn J, et al. 1992. Reactivation of unstable angina after the discontinuation of heparin. N. Engl. J. Med. 327:141-45
17. Granger CB, Miller JM, Bovill EG, et al. 1995. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acture coronary syndromes. Circulation 91:1929-35
18. Fennerty A, Thomas P, Backhouse G, et al. 1985. Audit of control of heparin treatment. Br. Med. J. 290:27-28
19. Wheeler AP, Jaquiss RD, Newman JH. 1988. Physician practices in the treatment of pulmonary embolism and deep-venous thrombosis. Arch. Int. Med. 148:1321-25
20. Cruickshank MK, Levine MN, Hirsh J, et al. 1991. A standard nomogram for the management of heparin therapy. Arch. Int. Med. 151:333-37
21. Hull RD, Raskob GE, Hirsh J, et al. 1986. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N. Engl. J. Med. 315:1109-14
22. Raschke RA, Reilly BM, Guidry JR, et al. 1993. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann. Intern. Med. 119: 874-81
23. Brandjes DPM, Heijboer H, Buller HR, et al. 1992. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N. Engl. J. Med. 327:1485-89
24. Hull RD, Raskob GE, Rosenbloom DR, et al. 1992. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch. Int. Med. 152:1589-95
25. Brill-Edwards P, Ginsberg S, Johnston M, et al. 1993. Establishing a therapeutic range for heparin therapy. Ann. Intern. Med. 119: 104-9
26. Warkentin TE, Kelton JG. 1991. Heparin-induced thrombocytopenia. Prog. Hemost. Thromb. 10:1-34
27. Boshkov LK, Warkentin TE, Hayward CPM, et al. 1993. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br. J. Haematol. 84: 322-28
28. Kelton JG, Sheridan D, Brian H, et al. 1984. Clinical usefulness of testing for a heparin-dependent platelet aggregation factor in patients with suspected heparin-associated thrombocytopenia. J. Lab. Clin. Med. 103: 606-12
29. (14)C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am. J. Clin. Pathol. 104(6): 648-54
30. Demers C, Ginsberg JS, Brill-Edwards P, et al. 1991. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 78:2194-97
31. Magnani HN. 1993. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb. Haemost. 70:554-61
32. Nand S. 1993. Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis. Am. J. Hematol. 43(4): 310-11
33. Matsuo T, Kario K, Chikahira Y, et al. 1992. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br. J. Haematol. 82(3): 627-29
34. Hirsh J, Levine MN. 1992. Low molecular weight heparin. Blood 79:1-17
35. Fareed J, Walenga JM, Hoppensteadt D, et al. 1988. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis 18 (Suppl. 3):3-15
36. Bara L, Samama MM. 1988. Pharmacokinetics of low molecular weight heparins. Acta Chir. Scand. 543:65-72
37. a. Effects of intravenous and subcutaneous injection in rabbits. Thromb. Haemost. 61:348-53
38. Anderson L-O, Barrowcliffe TW, Holmer E, et al. 1979. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb. Res. 115:531-38
39. Fareed J, Walenga JM, Racanelli A, et al. 1988. Validity of the newly established low molecular weight heparin standard in cross referencing low molecular weight heparins. Haemostasis 3(Suppl.):33-47
40. Barrowcliffe TW, Curtis AD, Johnson EA, et al. 1988. An international standard for low molecular weight heparin. Thromb. Haemost. 60:1-7
41. Holmer E, Soderberg K, Bergqvist D, et al. 1986. Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties. Haemostasis 16(Suppl. 2): 1-7
42. Carter CJ, Kelton JG, Hirsh J, et al. 1982. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparins and heparin. Blood 59:1239-45
43. Cade JF, Buchanan MR, Boneu B, et al. 1984. A comparison of the antithrombotic and haemorrrahagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb. Res. 35:613-25
44. Andriuoli G, Mastacchi R, Barnti M, et al. 1985. Comparison of the antithrombotic and hemorrhagic effects of heparin and a new low molecular weight heparin in the rat. Haemostasis 15:324-30
45. Lensing AW, Prins MH, Davidson BL, et al. 1995. Treatment of deep venous thrombosis with low-molecular-weight heparins. Arch. Int. Med. 155:601-7
46. Monreal M, Lafoz E, Salvador R, et al. 1989. Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkaalaemia. Eur. J. Clin. Pharmacol. 37: 415-18
47. Monreal M, Vinas L, Monreal L, et al. 1990. Heparin-related osteoporosis in rats. A comparative study between unfractionated heparin and a low molecular weight heparin. Haemostasis 20:204-7
48. Matzsch T, Bergqvist D, Hedner U, et al. 1990. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rates. Thromb. Haemost. 63:505-9
49. Shaughnessy SG, Young E, Deschamps P, Hirsh J. 1995. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 86: 1368-73
50. Warkentin TE, Levine MN, Hirsh J, et al. 1995. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332(20):1330-35
51. Forestier F, Daffos F, Capella-Pavlovsky M. 1984. Low molecular weight heparin (PH 10169) does not cross the placenta during the second trimester of pregnancy: study by direct foetal blood sampling under ultrasound. Thromb. Res. 34:557-60
52. Andrew M, Cade J, Buchanan MR, et al. 1983. Low-molecular weight heparin does not cross the placenta. Thromb. Haemost. 50:225 (Abstr.)
53. Omri A, Delaloye FJ, Andersen H, et al. 1989. Low-molecular-weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb. Haemost. 61:55-56
54. Melissari E, Parker CJ, Wilson NV, et al. 1992. Use of low molecular weight heparin in pregnancy. Thromb. Haemost. 68: 652-56
55. Sturridge F, de Swiet M, Letsky E. 1994. The use of low molecular weight heparin for thromboprophylaxis in pregnancy. Br. J. Obstet. Gynaecol. 101: 69-71
56. Wahlberg TB, Kher A. 1994. Low molecular weight heparin as thromboprophylaxis in pregnancy. A retrospective analysis from 14 European clinics. Haemostasis 24: 55-56
57. Ginsberg JS, Hirsh J. 1995. Use of antithrombotic agents during pregnancy. Chest 108(4):305-11S
58. Boneu B, Caranobe C, Cadroy Y, et al. 1988. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Sem. Thromb. Hemost. 14:18-27
59. Boneu B, Buchanan MR, Cade JF, et al. 1985. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo. Thromb. Res. 40:81-89
60. Kakkar VV, Murray WJG. 1985. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thromboembolism: a co-operative study. Br. J. Surg. 72:786-91
61. Kakkar VV, Cohen AT, Edmonson RA, et al. 1993. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 341:259-65
62. Bergqvist D, Matzsch T, Brumark U, et al. 1988. Low-molecular-weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br. J. Surg. 75: 888-91
63. Samama M, Bernard P, Bonnardot JP, et al. 1988. Low-molecular-weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br. J. Surg. 75:128-31
64. European Fraxiparin Study Group. 1988. Comparison of a low-molecular-weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br. J. Surg. 75:1058-63
65. Caen JP. 1988. A randomized double-blind study between a low-molecular-weight heparin Kabi 2165 and standard heparin in the prevention of deep-vein thrombosis in general surgery. A French mullicentre trial. Thromb. Haemost. 59:216-20
66. Leizorovicz A, Picolet H, Peyrieux JC, et al. 1991. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double-blind study comparing two doses of logiparin and standard heparin. Br. J. Surg. 78:412-16
67. Nurmohamed MT, Verhaeghe R, Haas S, et al. 1994. A comparative trial of a low molecular weight heparin (Enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am. J. Surg. 169:567-71
68. Turpie AGG, Levine MN, Hirsh J, et al. 1986. A randomized controlled trial of low-molecular-weight heparin (Enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N. Engl. J. Med. 315:925-29
69. Tørholm C, Broeng L, Jørgensen PS, et al. 1991. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery: a placebo controlled study. J. Bone Jt. Surg. Br. Vol. 73B:434-38
70. Lassen MR, Borris LC, Christiansen HM, et al. 1991. Prevention of thromboembolism in 190 hip arthroplasties. Acta Orthop. Scand. 62(1):33-38
71. Danish Enoxaparin Study Group. 1991. Low-molecular weight heparin (Enoxaparin) vs Dextran 70. Arch. Int. Med. 151: 1621-24
72. Levine MN, Hirsh J, Gent M, et al. 1991. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann. Intern. Med. 114(7):545-51
73. Eriksson BI, Kälebo P, Anthmyr BA, et al. 1991. Prevention of deep vein thrombosis and pulmonary embolism after total hip replacement. J. Bone Jt. Surg. Am. Vol. 73A(4):484-93
74. Leyvraz PF, Bachmann F, Hoek J, et al. 1991. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. Br. Med. J. 303:543-48
75. Colwell CW, Spiro TE, Trowbridge AA, et al. 1994. Use of Enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J. Bone Jt. Surg. 76A(1):3-14
76. Hull RD, Raskob GE, Pineo GF, et al. 1993. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N. Engl. J. Med. 329:1370-76
77. Hamulyak K, Lensing AWA, van der Meer J, et al. 1995. Subcutaneous low-molecular-weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Thromb. Haemost. 74(6):1428-31
78. Leclerc JR, Geerts WH, Desjardins L, et al. 1992. Prevention of deep vein thrombosis after major knee surgery - a randomized, double-blind trial comparing a low-molecular-weight heparin fragment (Enoxaparin) to placebo. Thromb. Haemost. 67(4): 417-23
79. Leclerc JR, Geerts WH, Desjardins L, et al. 1996. Prevention of venous thromboembolism after knee arthroplasty - a randomized, double-blind trial comparing a low molecular weight heparin fragment (Enoxparin) to Warfarin. Ann. Intern. Med. 124(7):619-26
80. Heit J, Berkowitz S, Bona R, et al. 1995. Efficacy and safety of Normiflow (a LMWH) compared to warfarin for prevention of venous thromboembolism following total knee replacement: a double-blind, dose-ranging study. Thromb. Haemost. 73(6):A739 (Abstr.)
81. Dahan R, Houlbert D, Caulin C, et al. 1986. Prevention of deep vein thrombosis in elderly medical patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 16:159-64
82. Bratt G, Tornebohm E, Grunqvist S, et al. 1985. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb. Haemost. 54:813-17
83. Holm HA, Ly B, Handeland GF, et al. 1986. Subcutaneous heparin treatment of deep venous thrombosis. A comparison of unfractionated and low molecular weight heparin. Haemostasis 16:30-37
84. Albada J, Nieuwenhuis HK, Sixma JJ. 1989. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin): results of a double-blind randomized study. Circulation 80: 935-40
85. Bratt G, Aberg W, Johansson M, et al. 1990. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (VDT). Thromb. Haemost. 64: 506-10
86. Harenberg J, Huck K, Bratsch H, et al. 1990. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. Haemostasis 20(Suppl. 1):205-19
87. Siegbahan A, Y-Hassan S, Boberg J, et al. 1989. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo. Thromb. Res. 55:267-78
88. Hull RD, Raskob GE, Pineo GF, et al. 1992. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N. Engl. J. Med. 326:975-88
89. Prandoni P, Lensing AW, Buller HR, et al. 1992. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339:441-45
90. Lopaciuk S, Meissner AJ, Filipecki S, et al. 1992. Subcutaneous low-molecular-weight-heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicentre trial. Thromb. Haemost. 68:14-18
91. Simonneau G, Charbonnier B, Decousus H, et al. 1993. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch. Int. Med. 153:1541-46
92. Lindmarker P, Holmstrom M, Granqvist S, et al. 1994. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thromb. Haemost. 72:186-90
93. Green D, Hull RD, Brant R, Pineo GF. 1992. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 339:1476
94. Pineo GF, Hull RD, Rosenbloom D, Raskob GE. 1994. A cost-effectiveness analysis of low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. Br. J. Haematol. 7:184 (Abstr.)
95. Levine M, Gent M, Hirsh J, et al. 1996. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N. Engl. J. Med. 334:677-81
96. Koopman MMW, Prandoni P, Piovella F, et al. 1996. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N. Engl. J. Med. 334:682-87
97. Meyer G, Brenot F, Pacouret G, et al. 1995. Subcutaneous low-molecular-weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. Thromb. Haemost. 74(6):1432-35
98. Hull RD, Pineo GF, Brant RF. 1996. Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clin. Appl. Thromb. Hemost. 2(1):S1-11